AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37356708
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL ExoFlo
Trial: 37356876
Drug: Faster aspart
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faster aspart insulin
Trial: 37357331
Drug: Camelina enriched
RxNorm normalized name: Camelina sativa seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camelina enriched crackers (35 g, twice daily for 12 weeks)
Trial: 37357331
Drug: Placebo crackers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo crackers (35 g, twice daily for 12 weeks)
Trial: 37357807
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg iron supplements taken in the morning with ascorbic acid (AA)
Trial: 37357807
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg iron supplements taken at different times of day without ascorbic acid (AA)
Trial: 37357904
Drug: Ivermectin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (200 µg/kg) and Albendazole (400 mg)
Trial: 37357904
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg) and Placebo
Trial: 37357950
Drug: barecetamab monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: barecetamab monotherapy at 20 mg/kg IV every 3 weeks
Trial: 37357950
Drug: barecetamab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: barecetamab (20 mg/kg IV) and cetuximab (400 mg/m2) combination therapy
Trial: 37357950
Drug: barecetamab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: barecetamab at 1, 3, 5, 10, and 20 mg/kg IV on days 1 and 28 and weekly
Trial: 37358545
Drug: Oral alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alcohol challenge
Trial: 37358640
Drug: Idelalisib containing
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idelalisib containing therapy
Trial: 37358640
Drug: Idelalisib after
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idelalisib after prior ibrutinib therapy
Trial: 37358640
Drug: Idelalisib without
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idelalisib without prior ibrutinib therapy
Trial: 37358858
Drug: Standard-course therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-course therapy (another 5 days of antimicrobials)
Trial: 37358858
Drug: Short-course therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course therapy (5 days of placebo)
Trial: 37358858
Drug: Short-course therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course therapy
Trial: 37358858
Drug: Standard-course therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-course therapy and Short-course therapy
Trial: 37358916
Drug: IBI112 (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI112 (subcutaneous 5-600 mg or intravenous 100 and 600 mg)
Trial: 37359242
Drug: Sotrastaurin 300
RxNorm normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotrastaurin 300 mg and Binimetinib 30 mg
Trial: 37359242
Drug: Sotrastaurin 200
RxNorm normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotrastaurin 200 mg and Binimetinib 45 mg
Trial: 37360346
Drug: Antioxidant treatment
RxNorm normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant treatment with lipoic acid
Trial: 37360352
Drug: DOSE protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOSE protocol (higher intensity walking)
Trial: 37360811
Drug: Low-intensity general
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity general fitness training sessions (twice a week for four weeks)
Trial: 37360864
Drug: Convidecia (heterologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convidecia (heterologous third dose)
Trial: 37360864
Drug: Convidecia (heterologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convidecia (heterologous second dose)
Trial: 37360864
Drug: CoronaVac (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac (three doses)
Trial: 37360864
Drug: CoronaVac (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac (second dose)
Trial: 37549680
Drug: CoronaVac (third
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac (third dose)
Trial: 37361483
Drug: Psychophysiologic symptom
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychophysiologic symptom relief therapy (PSRT) during a 13 week (approximately 44 hour) course.
Trial: 37363967
Drug: Laxative use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative use
Trial: 37363967
Drug: No laxative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No laxative use
Trial: 37363965
Drug: Tucatinib, Letrozole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tucatinib, Letrozole, and Palbociclib (TLP combination)
Trial: 37363992
Drug: Dostarlimab 500
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab 500 mg every 3 weeks for four cycles, then 1,000 mg every 6 weeks until progression
Trial: 37364000
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor pathway inhibitors (ARPI; e.g., enzalutamide, abiraterone acetate)
Trial: 37364000
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor pathway inhibitors (ARPI)
Trial: 37364033
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Care Physical Therapy
Trial: 37364220
Drug: Aspirin treatment
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin treatment for high-risk colorectal cancer
Trial: 37364590
Drug: CagriSema (cagrilintide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CagriSema (cagrilintide 2·4 mg + semaglutide 2·4 mg)
Trial: 37364590
Drug: semaglutide (2·4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide (2·4 mg)
Trial: 37364590
Drug: cagrilintide (2·4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cagrilintide (2·4 mg)
Trial: 37364683
Drug: 20-mg/d lutein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mg/d lutein supplementation
Trial: 37364685
Drug: HYP-CT (Hypnosis-enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYP-CT (Hypnosis-enhanced cognitive therapy)
Trial: 37364710
Drug: Ecnoglutide (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecnoglutide (subcutaneous injection)
Trial: 37365046
Drug: Home Blood
RxNorm normalized name: LifeSource Aneroid Home Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home Blood Pressure Monitoring (HBPM) combined with Collaborative Drug Therapy Management (CDTM)
Trial: 37365210
Drug: Tablet-based system
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based system combining structured symptoms questionnaire and 2-handed spiral drawing
Trial: 37365557
Drug: COVID-19 vaccination
RxNorm normalized name: COVID-19 VACCINE ADENOVIRUS-26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 vaccination with 3+ doses
Trial: 37365583
Drug: LNA-i-miR-221 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNA-i-miR-221 (5 mg/kg, 30-min IV infusion on 4 consecutive days)
Trial: 37365596
Drug: Pyrotinib 400
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib 400 mg daily plus letrozole 2.5 mg daily
Trial: 37365608
Drug: Lp(a) ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a) ≥ 50 mg/dL in DM group
Trial: 37365608
Drug: Lp(a) <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a) < 10 mg/dL in DM group
Trial: 37365608
Drug: Lp(a) ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a) ≥ 50 mg/dL in nonDM group
Trial: 37365608
Drug: Lp(a) <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a) < 30 mg/dL in nonDM group
Trial: 37365608
Drug: DM with
RxNorm normalized name: Novahistex DM with Decongestant
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DM with Lp(a) < 30 mg/dL
Trial: 37365608
Drug: DM with
RxNorm normalized name: Novahistex DM with Decongestant
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DM with Lp(a) ≥ 30 mg/dL
Trial: 37365618
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg daily initiated at least 15 days before PCI and maintained until the end of follow-up.
Trial: 37365656
Drug: AAC +
RxNorm normalized name: Acetylsalicylic acid plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAC + nicotine replacement therapy (NRT)
Trial: 37365665
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment (EBD/SEMS)
Trial: 37365881
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives (COCs) containing drospirenone and ethinylestradiol (EE)
Trial: 38858523
Drug: Retatrutide 1
RxNorm normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retatrutide 1 mg
Trial: 37366315
Drug: Retatrutide 4
RxNorm normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retatrutide 4 mg (combined initial doses of 2 mg and 4 mg)
Trial: 37366315
Drug: Retatrutide 8
RxNorm normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retatrutide 8 mg (combined initial doses of 2 mg and 4 mg)
Trial: 37366315
Drug: Retatrutide 12
RxNorm normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retatrutide 12 mg (initial dose of 2 mg)
Trial: 37366480
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment for one year
Trial: 37366590
Drug: TV-45070, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TV-45070, a topical semiselective sodium 1.7 channel (Nav1.7) blocker
Trial: 37366614
Drug: Cefepime 2000
RxNorm normalized name: cefepime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 2000 mg by 30-min intravenous infusions every 8 to 24 hours
Trial: 37366668
Drug: Silver Diamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver Diamine Fluoride (SDF) therapy with immediate rinsing (Group A)
Trial: 37366668
Drug: Silver Diamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver Diamine Fluoride (SDF) therapy with no rinsing for 30 min (Group B)
Trial: 37366919
Drug: Burden of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Burden of Therapy (BOTh) intervention
Trial: 37367978
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT): 300 mg clopidogrel on the first day followed by 75 mg daily for 12 days, 100 mg aspirin on the first day followed by 100 mg daily for 12 days, and guideline-based antiplatelet treatment until 90 days.
Trial: 37367978
Drug: Alteplase: intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase: intravenous alteplase (0.9 mg/kg; maximum dose, 90 mg) followed by guideline-based antiplatelet treatment beginning 24 hours after receipt of alteplase.
Trial: 37368100
Drug: Adavosertib 225
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib 225 mg twice daily on days 1-2 at 12-h intervals and once on day 3.
Trial: 37368401
Drug: App-based individually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App-based individually tailored self-management support (SELFBACK) adjunct to usual care
Trial: 37368401
Drug: Web-based nontailored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based nontailored self-management support (e-Help) adjunct to usual care
Trial: 37368512
Drug: Higher BMI
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher BMI (in models including both BMI and insulin sensitivity)
Trial: 37368929
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) with oral etoposide chemotherapy
Trial: 37368929
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) alone
Trial: 37368929
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum biomarkers (CRP, IL-6, IL-10, soluble tumor necrosis factor receptor-2)
Trial: 37369081
Drug: EV monotherapy
RxNorm normalized name: Summer's Eve Medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV monotherapy
Trial: 37369232
Drug: Orforglipron (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orforglipron (12 mg or greater)
Trial: 37369421
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of high-velocity, soft-tissue massage, and craniosacral techniques
Trial: 37369422
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days antibiotic therapy
Trial: 37369422
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days antibiotic therapy
Trial: 37369815
Drug: IO-tyrosine kinase
RxNorm normalized name: Io-Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IO-tyrosine kinase inhibitor (IO + TKI) combinations
Trial: 37369815
Drug: Dual immuno-oncology
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual immuno-oncology (IO + IO) therapy
Trial: 37369826
Drug: Basal long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal long-acting insulin
Trial: 37369955
Drug: Difelikefalin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difelikefalin (single intravenous doses)
Trial: 37370032
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with mFOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan), up to 5 cycles.
Trial: 37370032
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with mFOLFOXIRI
Trial: 37370174
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SoC) TB treatment + placebo
Trial: 37370174
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SoC) TB treatment + acetylsalicylic acid (ASA)
Trial: 37370174
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SoC) TB treatment + ibuprofen (Ibu)
Trial: 37370204
Drug: Facilitated allogeneic
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitated allogeneic hematopoietic stem cell transplant with tolerogenic CD8 + /T-cell receptor - facilitating cells (FCR001) and low-dose, nonmyeloablative conditioning.
Trial: 37373625
Drug: E4 15
RxNorm normalized name: Ethinylestradiol 15 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E4 15 mg once daily for 21 days
Trial: 37373857
Drug: Pneumatic compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pneumatic compression combined with standard venous thromboembolism (VTE) therapy
Trial: 37373857
Drug: Standard venous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard venous thromboembolism (VTE) therapy (control group)
Trial: 37375656
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of oligomalt (180 g/day)
Trial: 37375656
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of oligomalt (80 g/day) + maltodextrin (100 g/day)
Trial: 37375656
Drug: Maltodextrin (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin (180 g/day)
Trial: 37376480
Drug: PXVX0047 (Ad4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PXVX0047 (Ad4 and Ad7 components administered orally in a single dose to 11 subjects)
Trial: 37376480
Drug: Control Ad4/Ad7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Ad4/Ad7 vaccine (currently in use by the US military, administered to 3 subjects)
Trial: 37376989
Drug: Target LDL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target LDL cholesterol <70 mg/dL with >50% LDL cholesterol reduction from baseline
Trial: 37376989
Drug: Target LDL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target LDL cholesterol <70 mg/dL with <50% LDL cholesterol reduction from baseline
Trial: 37376989
Drug: Target LDL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target LDL cholesterol 100±10 mg/dL
Trial: 37377385
Drug: Tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 10 mg daily
Trial: 37377385
Drug: Methotrexate 25
RxNorm normalized name: methotrexate 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 25 mg subcutaneously weekly
Trial: 37377613
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg i.v. every 3 weeks and cabozantinib 60 mg orally once daily
Trial: 37377890
Drug: Intravenous RNA-electroporated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous RNA-electroporated cMET-directed CAR T cells (1 × 10e8 T cells/dose, up to six infusions)
Trial: 37377890
Drug: Intravenous RNA-electroporated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous RNA-electroporated cMET-directed CAR T cells
Trial: 37378754
Drug: eptinezumab 100
RxNorm normalized name: EPTINEZUMAB 100 mg in 1 mL INTRAVENOUS INJECTION [Vyepti]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eptinezumab 100 mg, 300 mg
Trial: 37378806
Drug: Intravenous Immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Immunoglobulin (IVIg) at 2.0 g/kg induction dose followed by maintenance doses of 0.5, 1.0 or 2.0 g/kg every 3 weeks for 24 weeks
Trial: 37378860
Drug: CC-90001 (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-90001 (100, 200, or 400 mg) administered once daily for 12 weeks
Trial: 37378972
Drug: Pharmacotherapy (varenicline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (varenicline, dual-form nicotine replacement, or their combination) and behavioral smoking cessation intervention with weight management and physical activity support
Trial: 37378974
Drug: Cognitive-Behavioral Case
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Case Management (CBCM) with Fluoxetine for 26 weeks
Trial: 37379001
Drug: 10-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day course of antibiotics
Trial: 37379158
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus platinum-based chemotherapy (experimental group)
Trial: 37379495
Drug: Gilteritinib 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gilteritinib 120 mg once daily
Trial: 37379495
Drug: Gilteritinib as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gilteritinib as single-agent maintenance therapy
Trial: 37379502
Drug: Lazertinib 240
RxNorm normalized name: lazertinib 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazertinib 240 mg once daily orally
Trial: 37379502
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg once daily orally
Trial: 37379532
Drug: Sputnik V
RxNorm normalized name: Sputnik V
DrugBank: Gam-COVID-Vac (DB15848)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sputnik V vaccine
Trial: 37379532
Drug: Ocrelizumab treatment
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab treatment
Trial: 37379764
Drug: Avelumab plus
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab plus binimetinib 45 mg
Trial: 37379764
Drug: Avelumab plus
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab plus binimetinib 30 mg
Trial: 37379764
Drug: Talazoparib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib plus binimetinib 45 mg
Trial: 37379764
Drug: Talazoparib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib plus binimetinib 30 mg